178 related articles for article (PubMed ID: 7579442)
1. Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors.
Rosti V; Bergamaschi G; Lucotti C; Danova M; Carlo-Stella C; Locatelli F; Tonon L; Mazzini G; Cazzola M
Blood; 1995 Nov; 86(9):3387-93. PubMed ID: 7579442
[TBL] [Abstract][Full Text] [Related]
2. c-kit expression by CD34+ bone marrow progenitors and inhibition of response to recombinant human interleukin-3 following exposure to c-kit antisense oligonucleotides.
Catlett JP; Leftwich JA; Westin EH; Grant S; Huff TF
Blood; 1991 Dec; 78(12):3186-91. PubMed ID: 1720696
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
Szczylik C; Skórski T; Malaguarnera L; Hetman J; Chen ST; Calabretta B
Folia Histochem Cytobiol; 1996; 34(3-4):129-34. PubMed ID: 8967957
[TBL] [Abstract][Full Text] [Related]
4. c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.
Rosti V; Bergamaschi G; Ponchio L; Cazzola M
Leukemia; 1992 Jan; 6(1):1-7. PubMed ID: 1736009
[TBL] [Abstract][Full Text] [Related]
5. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
[TBL] [Abstract][Full Text] [Related]
6. Expression and physiologic significance of Kit ligand and stem cell tyrosine kinase-1 receptor ligand in normal human CD34+, c-Kit+ marrow cells.
Ratajczak MZ; Kuczynski WI; Sokol DL; Moore JS; Pletcher CH; Gewirtz AM
Blood; 1995 Sep; 86(6):2161-7. PubMed ID: 7545021
[TBL] [Abstract][Full Text] [Related]
7. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
8. Implication of a new molecule IK in CD34+ hematopoietic progenitor cell proliferation and differentiation.
Cao LX; Le Bousse-Kerdiles MC; Clay D; Oshevski S; Jasmin C; Krief P
Blood; 1997 May; 89(10):3615-23. PubMed ID: 9160666
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells.
Weber-Nordt RM; Henschler R; Schott E; Wehinger J; Behringer D; Mertelsmann R; Finke J
Blood; 1996 Oct; 88(7):2549-58. PubMed ID: 8839847
[TBL] [Abstract][Full Text] [Related]
10. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.
Ratajczak MZ; Hijiya N; Catani L; DeRiel K; Luger SM; McGlave P; Gewirtz AM
Blood; 1992 Apr; 79(8):1956-61. PubMed ID: 1562723
[TBL] [Abstract][Full Text] [Related]
11. Growth of erythroid colonies in chronic myelogenous leukemia is independent of erythropoietin only in the presence of steel factor.
Issaad C; Vainchenker W
Blood; 1994 Nov; 84(10):3447-56. PubMed ID: 7524739
[TBL] [Abstract][Full Text] [Related]
12. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture.
Simmons PJ; Aylett GW; Niutta S; To LB; Juttner CA; Ashman LK
Exp Hematol; 1994 Feb; 22(2):157-65. PubMed ID: 7507857
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations.
Chasty R; Whetton A; Lucas G
Leuk Res; 1996 May; 20(5):391-5. PubMed ID: 8683978
[TBL] [Abstract][Full Text] [Related]
14. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor.
Lemoli RM; Tafuri A; Fortuna A; Petrucci MT; Ricciardi MR; Catani L; Rondelli D; Fogli M; Leopardi G; Ariola C; Tura S
Blood; 1997 Feb; 89(4):1189-96. PubMed ID: 9028941
[TBL] [Abstract][Full Text] [Related]
15. Lineage-specific requirement of c-abl function in normal hematopoiesis.
Caracciolo D; Valtieri M; Venturelli D; Peschle C; Gewirtz AM; Calabretta B
Science; 1989 Sep; 245(4922):1107-10. PubMed ID: 2672339
[TBL] [Abstract][Full Text] [Related]
16. Cationic lipid mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: uptake, biological effects and modulation of gene expression.
Albrecht T; Schwab R; Peschel C; Engels HJ; Fischer T; Huber C; Aulitzky WE
Ann Hematol; 1996 Feb; 72(2):73-9. PubMed ID: 8597610
[TBL] [Abstract][Full Text] [Related]
17. Separation of myeloid and erythroid progenitors based on expression of CD34 and c-kit.
De Jong MO; Wagemaker G; Wognum AW
Blood; 1995 Dec; 86(11):4076-85. PubMed ID: 7492763
[TBL] [Abstract][Full Text] [Related]
18. Antisense myb inhibition of purified erythroid progenitors in development and differentiation is linked to cycling activity and expression of DNA polymerase alpha.
Valtieri M; Venturelli D; Caré A; Fossati C; Pelosi E; Labbaye C; Mattia G; Gewirtz AM; Calabretta B; Peschle C
Blood; 1991 Mar; 77(6):1181-90. PubMed ID: 1705831
[TBL] [Abstract][Full Text] [Related]
19. Raf-1 protein is required for growth factor-induced proliferation of primitive hematopoietic progenitors stimulated with synergistic combinations of cytokines.
Muszynski KW; Ruscetti FW; Gooya JM; Linnekin DM; Keller JR
Stem Cells; 1997; 15(1):63-72. PubMed ID: 9007224
[TBL] [Abstract][Full Text] [Related]
20. Raf-1 protein is required for growth factor-induced proliferation of hematopoietic cells.
Muszynski KW; Ruscetti FW; Heidecker G; Rapp U; Troppmair J; Gooya JM; Keller JR
J Exp Med; 1995 Jun; 181(6):2189-99. PubMed ID: 7539043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
